Abbatis, Grow Life, Cannabis Science: Which Are the Best Marijuana Investments?
The United States and Canada have both been on the forefront of cannabis policy changes over the past couple years. In the U.S., 17 states have legalized medical marijuana, two states have legalized adult use of marijuana, and many more states have ballot measures in place for the November 2014 elections. In Canada, the newly established Marihuana for Medical Purposes (MMPR) regulations have opened up the market to cannabis producers and make it much safer, easier, and more convenient for Canadian citizens to fill medical declarations.
Despite these dramatic new changes, investors have relatively few options for capitalizing on the industry’s growth. Cannabis remains illegal on a federal level in the U.S., which has kept many public companies out of the production side of the business. At the same time, Canada’s reforms have been relatively strict with only a handful of the 400-plus applicants receiving approval to become legal and regulated cannabis producers.
In this article, we’ll take a look at some of the best ways for investors to gain exposure to the burgeoning cannabis industry and which country might yield the best opportunities. In particular, we’ll look at Abattis Bioceuticals Inc. (OTC:ATTBF) (CSE:ATT) — a multi-faceted cannabis company involved in numerous areas of the industry that we recently profiled in a video interview with CEO Michael Withrow below — and other popular companies in the space like GrowLife Inc. (OTCBB:PHOT) and Cannabis Science Inc. (OTCBB:CBIS).